Regenerative medicine company, Regeneus (ASX: RGS) announced further results from the clinical research study that is tracking the safety and effectiveness of its innovative cell therapy, HiQCell, in the treatment of osteoarthritis.
The interim report of 386 patients as at 21 July 2014 has found that:
- Pain has continued to reduce at two years post-treatment;
- At one year post-treatment, 63 of 86 patients reported more than a 30% reduction in pain;
- At two years post-treatment 14 of 17 patients reported more than a 30 % reduction in pain. The 14 patients experienced an average pain reduction of 84% at two years post-treatment;
- Patients also reported significant improvements from pre-treatment in knee-function, sleep quality and reduced pain medications;
- HiQCell is a safe therapy and well tolerated by patients.
The HiQCell Joint Registry is the first of its kind in the long-term follow-up of patients undergoing stem cell therapy using the patient’s own fat-derived stem cells. The study has been approved by a human research ethics committee. As at 21 July 2014, a total of 386 patients are included in the Joint Registry. Patients in the Registry will continue to be followed for up to 5 years with analysis updated regularly.
Professor Graham Vesey, CEO of Regeneus, comments, “The registry data is demonstrating that HiQCell has a therapeutic benefit for longer than 2 years. We are now also beginning to see very encouraging data from patients that have had cells frozen for future injections. This combination of the long-term effect from HiQCell and the successful storage of cells for repeat injections in the future, means that HiQCell can be used to treat joint pain for many years. This is particularly important for patients that are too young for joint replacement or are simply looking to delay joint replacement”.
The full report will be available to read on the HiQCell website www.hiqcell.com.au